Antibody therapies, oncology drug development, and biotech research by Compass Therapeutics

  • Daria Chernytska
  • 17.11.2026
Compass Therapeutics appoints Sapna Mehtani as vice president and head of intellectual property
Compass Therapeutics has announced the appointment of Sapna Mehtani as vice president and head of intellectual property. The addition brings new leadership to the company’s strategy in ...
  • Ksenia Gerey
  • 24.10.2026
Phase 2 3 COMPANION 002 study findings released by Compass Therapeutics
Compass Therapeutics has announced the presentation of results from its Phase 2 3 COMPANION 002 trial targeting previously treated advanced biliary tract cancer. The findings are being shared at ...